The Chinese pharma market

China’s pharmaceutical market is growing almost 15% annually and is expected to be about $100 billion dollars in 2017. Drug regulations are however still quite complicated in China and the required drug documentation for approval is extensive. 

Pharma Vision 2020

The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investments. Further, the government introduced mechanisms such as the Drug Price Control Order and the National Pharmaceutical Pricing Authority to deal with the issue of affordability and availability of medicines.

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A bright future for Indian pharma
The Indian pharmaceutical market size is expected to grow to US$ 100 billion by 2025, driven by increasing consumer spending, rapid urbanisation, and raising healthcare insurance among others.Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise. The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

the Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

 

Generic drugs form largest segment

Generic drugs form the largest segment on the Indian pharmaceuticals market

 

• With 70 per cent of market share (in terms of revenues), generic drugs form the largest segment of the Indian pharmaceutical sector.

• India supply 20 per cent of global generic medicines market exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years

• Over the Counter (OTC) medicines and patented drugs constitute 21 per cent and 9 per cent, respectively, of total market revenues of US$ 20 billion

Generic versus branded name in India
From a public health perspective, it is desirable for drugs to be marketed by their generic names. However, drugs are generally marketed by their brand names though there is a legal requirement to mention generic names in the labels.
The Indian pharmaceutical industry is generally of the view that the practice of deriving brand names from parts of generic names is common throughout the world. The practice of using parts of INN stems is not specifically prohibited under Indian law; moreover, this does not cause confusion since the Indian regulations require the generic name to be shown more prominently than the brand name.
 
 
 
 
 
 
 
 
 
 
 
Further, the use of stems in the brand name may help in easy identification of the brand with the generic substance. It may also be cost-effective for small companies to use a brand name that contains a part of an INN without having to invest substantially on developing unique brand names. Large companies want to have unique brand names identifying the name with the company, since they want to build the loyalty of the customer to the company and all its brands. Small companies, with a smaller range of products, need to develop loyalty to particular brands. It is easier to create names using parts of generic names, as they are easy to recall and identify.
 
Some stakeholders also hold the view that while it may be ideal to have generic names for drug promotion, it may not be a practical policy in India where most drugs are marketed by the private sector. However, the practice of using INN stems in brand names may lead to confusion due to the availability of drugs that sound alike and look alike.

 

About Pharmanaming.com and GNN

The Global Naming Network (GNN), headquartered in Geneva, is the world's largest network of independent naming and brand identity agencies.

 

With around 240 cooperating naming and branding specialists in 16  countries, from Beijing to New York and from Seoul to Paris, GNN works for clients ranging from large multinationals to small startups all over the world.

Pharmaceutical projects are coordinated from the GNN office in Amsterdam by the pharma naming specialists of Globrands.

The www.pharmanaming.com website is dedicated to our expertise and work for the health & pharma industry.

 

Please contact us for more information.

20

offices in 16 countries

240

creatives, strategists & consultants

GNN offices

China                     South Korea

France                   Italy
Germany               Japan

Netherlands          UK

India                      Singapore

Spain                     Canada

Switzerland          Russia

USA                       Dubai

5000

projects successfully executed

Pages

home                           name to brand

health & pharma        people

regulatory                   test & submit

India                             FDA

work                             blog

clients                          contact

20000

linguistic professionals worldwide

Globrands the name behind the brands

© 2020 by Globrands consultancy group

Herengracht 122, 1015 BT Amsterdam, the Netherlands

call +31206238555 or mail to pharma@globrands.com  

 

  • White LinkedIn Icon